Share on StockTwits

Analysts at HC Wainwright initiated coverage on shares of Celsion (NASDAQ:CLSN) in a research report issued to clients and investors on Friday, reports. The firm set a “buy” rating and a $8.00 price target on the stock. HC Wainwright’s price target points to a potential upside of 97.53% from the company’s current price.

Celsion (NASDAQ:CLSN) traded up 13.65% on Friday, hitting $4.603. 1,045,480 shares of the company’s stock traded hands. Celsion has a 52 week low of $3.3784 and a 52 week high of $42.5225. The stock has a 50-day moving average of $3.85 and a 200-day moving average of $4.8. The company’s market cap is $62.6 million.

Celsion (NASDAQ:CLSN) last released its earnings data on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.23) by $0.08. The company had revenue of $0.13 million for the quarter. Analysts expect that Celsion will post $-0.59 EPS for the current fiscal year.

Celsion Corporation (NASDAQ:CLSN) is an oncology drug development company focused on improving treatment for those suffering with aggressive and difficult to treat forms of cancer.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.